These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 19924252)

  • 21. Combination of panobinostat with ponatinib synergistically overcomes imatinib-resistant CML cells.
    Matsuda Y; Yamauchi T; Hosono N; Uzui K; Negoro E; Morinaga K; Nishi R; Yoshida A; Kimura S; Maekawa T; Ueda T
    Cancer Sci; 2016 Jul; 107(7):1029-38. PubMed ID: 27166836
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 5-aminoimidazole-4-carboxamide riboside enhances effect of ionizing radiation in PC3 prostate cancer cells.
    Isebaert SF; Swinnen JV; McBride WH; Begg AC; Haustermans KM
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1515-23. PubMed ID: 21944462
    [TBL] [Abstract][Full Text] [Related]  

  • 23. AMPK activator acadesine fails to alleviate isoniazid-caused mitochondrial instability in HepG2 cells.
    Zhang TG; Ikejima T; Hayashi T; Zhao J; Wang YM; Peng SQ
    J Appl Toxicol; 2017 Oct; 37(10):1219-1224. PubMed ID: 28556920
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acadesine inhibits tissue factor induction and thrombus formation by activating the phosphoinositide 3-kinase/Akt signaling pathway.
    Zhang W; Wang J; Wang H; Tang R; Belcher JD; Viollet B; Geng JG; Zhang C; Wu C; Slungaard A; Zhu C; Huo Y
    Arterioscler Thromb Vasc Biol; 2010 May; 30(5):1000-6. PubMed ID: 20185792
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of crosstalk between Bcr-Abl and PKC signaling by PEITC, augments imatinib sensitivity in chronic myelogenous leukemia cells.
    Roy M; Sarkar R; Mukherjee A; Mukherjee S
    Chem Biol Interact; 2015 Dec; 242():195-201. PubMed ID: 26456889
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting of heat shock protein 32 (Hsp32)/heme oxygenase-1 (HO-1) in leukemic cells in chronic myeloid leukemia: a novel approach to overcome resistance against imatinib.
    Mayerhofer M; Gleixner KV; Mayerhofer J; Hoermann G; Jaeger E; Aichberger KJ; Ott RG; Greish K; Nakamura H; Derdak S; Samorapoompichit P; Pickl WF; Sexl V; Esterbauer H; Schwarzinger I; Sillaber C; Maeda H; Valent P
    Blood; 2008 Feb; 111(4):2200-10. PubMed ID: 18024796
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anthelmintic niclosamide suppresses transcription of BCR-ABL fusion oncogene via disabling Sp1 and induces apoptosis in imatinib-resistant CML cells harboring T315I mutant.
    Jin B; Wang C; Shen Y; Pan J
    Cell Death Dis; 2018 Jan; 9(2):68. PubMed ID: 29358661
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms.
    Lan X; Zhao C; Chen X; Zhang P; Zang D; Wu J; Chen J; Long H; Yang L; Huang H; Carter BZ; Wang X; Shi X; Liu J
    J Hematol Oncol; 2016 Nov; 9(1):129. PubMed ID: 27884201
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Resveratrol promotes autophagic cell death in chronic myelogenous leukemia cells via JNK-mediated p62/SQSTM1 expression and AMPK activation.
    Puissant A; Robert G; Fenouille N; Luciano F; Cassuto JP; Raynaud S; Auberger P
    Cancer Res; 2010 Feb; 70(3):1042-52. PubMed ID: 20103647
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The chimeric ubiquitin ligase SH2-U-box inhibits the growth of imatinib-sensitive and resistant CML by targeting the native and T315I-mutant BCR-ABL.
    Ru Y; Wang Q; Liu X; Zhang M; Zhong D; Ye M; Li Y; Han H; Yao L; Li X
    Sci Rep; 2016 Jun; 6():28352. PubMed ID: 27329306
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells.
    Bartholomeusz GA; Talpaz M; Kapuria V; Kong LY; Wang S; Estrov Z; Priebe W; Wu J; Donato NJ
    Blood; 2007 Apr; 109(8):3470-8. PubMed ID: 17202319
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PF‑114, a novel selective inhibitor of BCR‑ABL tyrosine kinase, is a potent inducer of apoptosis in chronic myelogenous leukemia cells.
    Ivanova ES; Tatarskiy VV; Yastrebova MA; Khamidullina AI; Shunaev AV; Kalinina AA; Zeifman AA; Novikov FN; Dutikova YV; Chilov GG; Shtil AA
    Int J Oncol; 2019 Jul; 55(1):289-297. PubMed ID: 31115499
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Silencing of suppressor of cytokine signaling-3 due to methylation results in phosphorylation of STAT3 in imatinib resistant BCR-ABL positive chronic myeloid leukemia cells.
    Al-Jamal HA; Jusoh SA; Yong AC; Asan JM; Hassan R; Johan MF
    Asian Pac J Cancer Prev; 2014; 15(11):4555-61. PubMed ID: 24969884
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Montelukast, a cysteinyl leukotriene receptor antagonist, inhibits the growth of chronic myeloid leukemia cells through apoptosis.
    Zovko A; Yektaei-Karin E; Salamon D; Nilsson A; Wallvik J; Stenke L
    Oncol Rep; 2018 Aug; 40(2):902-908. PubMed ID: 29845257
    [TBL] [Abstract][Full Text] [Related]  

  • 35. AICAR and metformin, but not exercise, increase muscle glucose transport through AMPK-, ERK-, and PDK1-dependent activation of atypical PKC.
    Sajan MP; Bandyopadhyay G; Miura A; Standaert ML; Nimal S; Longnus SL; Van Obberghen E; Hainault I; Foufelle F; Kahn R; Braun U; Leitges M; Farese RV
    Am J Physiol Endocrinol Metab; 2010 Feb; 298(2):E179-92. PubMed ID: 19887597
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A modified DAW-22 compound F-B1 inhibits Bcr/Abl and induces apoptosis in chronic myelogenous leukemia cells.
    Wang F; Wang J; Chong Z; Mu Y
    Anticancer Drugs; 2019 Feb; 30(2):159-166. PubMed ID: 30422832
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Apoptosis and erythroid differentiation triggered by Bcr-Abl inhibitors in CML cell lines are fully distinguishable processes that exhibit different sensitivity to caspase inhibition.
    Jacquel A; Colosetti P; Grosso S; Belhacene N; Puissant A; Marchetti S; Breittmayer JP; Auberger P
    Oncogene; 2007 Apr; 26(17):2445-58. PubMed ID: 17043649
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bone marrow-derived mesenchymal stromal cells promote resistance to tyrosine kinase inhibitors in chronic myeloid leukemia via the IL-7/JAK1/STAT5 pathway.
    Zhang X; Tu H; Yang Y; Jiang X; Hu X; Luo Q; Li J
    J Biol Chem; 2019 Aug; 294(32):12167-12179. PubMed ID: 31235520
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Autophagy induction by Bcr-Abl-expressing cells facilitates their recovery from a targeted or nontargeted treatment.
    Crowley LC; Elzinga BM; O'Sullivan GC; McKenna SL
    Am J Hematol; 2011 Jan; 86(1):38-47. PubMed ID: 21132731
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CD-200 induces apoptosis and inhibits Bcr-Abl signaling in imatinib-resistant chronic myeloid leukemia with T315I mutation.
    Fang Z; Jung KH; Yan HH; Kim SJ; Son MK; Rumman M; Lee H; Kim KW; Yoo HD; Hong SS
    Int J Oncol; 2015 Jul; 47(1):253-61. PubMed ID: 25963192
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.